期刊
HEPATIC ONCOLOGY
卷 2, 期 4, 页码 371-379出版社
FUTURE MEDICINE LTD
DOI: 10.2217/hep.15.26
关键词
clinical trial; hepatocellular carcinoma; molecular classification; molecular targeted therapy
类别
资金
- FLAGS Foundation
- Nuovo-Soldati Cancer Research Foundation
- Geneva University Hospital
- NIH/NIDDK [DK099558]
- Irma T Hirschl Trust
- Dr Harold and Golden Lamport Research Award
Genomic profiling of hepatocellular carcinoma (HCC) tumors has elucidated recurrent molecular aberrations common or specific to disease etiology, patient race or geographic regions, allowing the classification of HCC tumors into subclasses sharing similar molecular and clinical characteristics. Previously reported transcriptome-based molecular subclasses have highlighted several common themes. Aggressive tumors are characterized by TP53 inactivation mutations and activation of pro-oncogenic signaling pathways, and further subclassified according to expression of stemness markers. The stemness marker-negative aggressive tumors display preferential TGF-beta activation. Another group of less aggressive tumors contains a subclass characterized by CTNNB1 mutations accompanied with overexpression of liver-specific WNT targets such as GLUL. Molecular therapies selectively targeting features of the HCC subclasses have suggested their utility in enriching potential responders in clinical trials and guiding therapeutic decision-making for HCC patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据